ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Nature Medicine

Volumn 19, Issue 2, 2013, Pages 202-208

  Souers, Andrew J ^a   Leverson, Joel D ^a   Boghaert, Erwin R ^a   Ackler, Scott L ^a   Catron, Nathaniel D ^a   Chen, Jun ^a   Dayton, Brian D ^a   Ding, Hong ^a   Enschede, Sari H ^a   Fairbrother, Wayne J ^b   Huang, David C S ^c,d   Hymowitz, Sarah G ^b   Jin, Sha ^a   Khaw, Seong Lin ^c,d   Kovar, Peter J ^a   Lam, Lloyd T ^a   Lee, Jackie ^b   Maecker, Heather L ^b   Marsh, Kennan C ^a   Mason, Kylie D ^c,d,e   Mitten, Michael J ^a   Nimmer, Paul M ^a   Oleksijew, Anatol ^a   Park, Chang H ^a   Park, Cheol Min ^a,g   Phillips, Darren C ^a   Roberts, Andrew W ^c,d,e   Sampath, Deepak ^b   Seymour, John F ^d,f   Smith, Morey L ^a   Sullivan, Gerard M ^a   Tahir, Stephen K ^a   Tse, Chris ^a   Wendt, Michael D ^a   Xiao, Yu ^a   Xue, John C ^a   Zhang, Haichao ^a   Humerickhouse, Rod A ^a   Rosenberg, Saul H ^a   Elmore, Steven W ^a   more..

^a ABBVIE INC   (United States)

^b GENENTECH INC   (United States)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g Nanyang Technological University   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 199; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN STRUCTURE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE; TUMOR CELL DESTRUCTION; X RAY CRYSTALLOGRAPHY;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PLATELETS; CELL SURVIVAL; DOGS; FEMALE; HELA CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873540049     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3048     Document Type: Article

References (50)

1. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000 (Pubitemid 30046295)
2. Adams, J.M. & Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324-1337 (2007 (Pubitemid 46328466)
3. Youle, R.J. & Strasser, A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59 (2008
4. Tsujimoto, Y., Cossman, J., Jaffe, E. & Croce, C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1440-1443 (1985 (Pubitemid 15041322)
5. Cleary, M.L., Smith, S.D. & Sklar, J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47, 19-28 (1986 (Pubitemid 17181529)
6. Boise, L.H. et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608 (1993 (Pubitemid 23259741)
7. Vaux, D.L., Cory, S. & Adams, J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440-442 (1988
8. Huang, J.Z. et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99, 2285-2290 (2002 (Pubitemid 34525409)
9. Minn, A.J., Rudin, C.M., Boise, L.H. & Thompson, C.B. Expression of bcl-xl can confer a multidrug resistance phenotype. Blood 86, 1903-1910 (1995
10. Amundson, S.A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101-6110 (2000
11. Zhang, H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14, 943-951 (2007 (Pubitemid 46655455)
12. Mason, K.D. et al. Programmed anuclear cell death delimits platelet life span. Cell 128, 1173-1186 (2007 (Pubitemid 46427871)
13. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005 (Pubitemid 40825512)
14. Park, C.M. et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 51, 6902-6915 (2008
15. Tse, C. et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008
16. Wilson, W.H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149-1159 (2010
17. Roberts, A.W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488-496 (2012
18. Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011
19. Petros, A.M. et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. USA 98, 3012-3017 (2001 (Pubitemid 32220791)
20. Muchmore, S.W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335-341 (1996
21. Wendt, M.D. Discovery of ABT-263, a Bcl-family protein inhibitor: Observations on targeting a large protein-protein interaction. Expert Opin. Drug. Discov. 3, 1123-1143 (2008
22. Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 275, 983-986 (1997 (Pubitemid 27087715)
23. Lee, E.F. et al. Crystal structure of ABT-737 complexed with Bcl-xL: Implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 14, 1711-1713 (2007 (Pubitemid 47278856)
24. Atwell, S., Ultsch, M., De Vos, A.M. & Wells, J.A. Structural plasticity in a remodeled protein-protein interface. Science 278, 1125-1128 (1997 (Pubitemid 27517894)
25. Wendt, M.D. et al. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J. Med. Chem. 49, 1165-1181 (2006 (Pubitemid 43221663)
26. Bruncko, M. et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 50, 641-662 (2007 (Pubitemid 46332978)
27. Harada, H., Quearry, B., Ruiz-Vela, A. & Korsmeyer, S.J. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc. Natl. Acad. Sci. USA 101, 15313-15317 (2004 (Pubitemid 39441538)
28. Del Gaizo Moore, V., Schlis, K.D., Sallan, S.E., Armstrong, S.A. & Letai, A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111, 2300-2309 (2008 (Pubitemid 351451437)
29. Shoemaker, A.R. et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 14, 3268-3277 (2008
30. Singh, R.R. et al. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 24, 1025-1036 (2010
31. Ackler, S. et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumors in vivo. Br. J. Pharmacol. 167, 881-891 (2012
32. Marschitz, I. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. Am. J. Clin. Pathol. 113, 219-229 (2000
33. Samuel, S. et al. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol. Ther. 18, 2094-2103 (2010
34. Rampello, E., Fricia, T. & Malaguarnera, M. The management of tumor lysis syndrome. Nat. Clin. Pract. Oncol. 3, 438-447 (2006 (Pubitemid 44203816)
35. American Cancer Society. Cancer Facts & Figures 2011. (2011
36. Sawas, A., Diefenbach, C. & O'Connor, O.A. New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr. Opin. Hematol. 18, 280-287 (2011
37. Bea, S. et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression based survival prediction. Blood 106, 3183-3190 (2005 (Pubitemid 41565917)
38. Iqbal, J. et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J. Clin. Oncol. 24, 961-968 (2006 (Pubitemid 46638851)
39. Irish, J.M. et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 109, 2589-2596 (2007 (Pubitemid 46425906)
40. Coustan-Smith, E. et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87, 1140-1146 (1996 (Pubitemid 26043542)
41. Campàs, C. et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp. Hematol. 34, 1663-1669 (2006 (Pubitemid 44839000)
42. Cimmino, A. et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 102, 13944-13949 (2005 (Pubitemid 41377683)
43. Calin, G.A. et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. USA 105, 5166-5171 (2008 (Pubitemid 351738528)
44. Matsumura, N. et al. mRNA display selection of a high-affinity, Bcl-X(L)-specific binding peptide. FASEB J. 24, 2201-2210 (2010
45. Roberts, A.W. et al. Selective inhibition of BCL-2 is active against chronic lymphocytic leukemia (CLL): First clinical experience with the BH3-mimetic ABT-199. Abstract 546 (European Hematology Association 2012, Amsterdam, The Netherlands, June 14-17, 2012
46. La Thangue, N.B. & Kerr, D.J. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587-596 (2011
47. Zhang H., Nimmer, P., Rosenberg, S.H., Ng, S.C. & Joseph, M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal. Biochem. 307, 70-75 (2002
48. Chen, J. et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol. Cancer Ther. 10, 2340-2349 (2011
49. Phillips, D.C., Garrison, S.P., Jeffers, J.R. & Zambetti, G.P. Assays to measure p53-dependent and -independent apoptosis. Methods Mol. Biol. 559, 143-159 (2009
50. Mason, K.D. et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23, 2034-2041 (2009